WAY 195725

Drug Profile

WAY 195725

Alternative Names: WAY-195725

Latest Information Update: 10 Aug 2009

Price : $50

At a glance

  • Originator Wyeth
  • Class Antirheumatics
  • Mechanism of Action Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Dysmenorrhoea; Osteoarthritis; Rheumatoid arthritis

Most Recent Events

  • 10 Aug 2009 Discontinued - Phase-I for Rheumatoid arthritis in USA (PO)
  • 10 Aug 2009 Discontinued - Phase-I for Osteoarthritis in USA (PO)
  • 10 Aug 2009 Discontinued - Phase-I for Dysmenorrhoea in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top